Test Price
5,900 AED✅ Home Collection Available
OncoPro PD‑L1 Circulating Tumor Cells Test in UAE | 5,900 AED | DHA Licensed | DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The OncoPro PD‑L1 Circulating Tumor Cells (CTC) test is a liquid biopsy that quantifies PD‑L1 protein expression on circulating tumor cells, directly guiding immunotherapy decisions for lung, breast, and urothelial cancers. This non‑invasive assay delivers real‑time biomarker evaluation without the burdens of tissue biopsy.
| Feature | Our OncoPro PD‑L1 CTC Test | Closest Alternative (Tissue PD‑L1 IHC) |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity (ISO 9001:2015 verified) | Variable; depends on biopsy quality and fixation artefacts |
| Methodology | Immunomagnetic Enrichment + PD‑L1 Immunofluorescence (LC‑MS/MS supported) | Immunohistochemistry (e.g., Dako 22C3) on formalin‑fixed tissue |
| Speed & Convenience | Home collection in 8 mL EDTA preservative; results in 21 working days | Requires invasive biopsy scheduling; 7–14 working days |
Physician Insight & Safety Protocols
“As a diagnostic radiologist specializing in oncology imaging, I understand the critical role biomarker profiling plays in guiding immunotherapy. The OncoPro PD‑L1 CTC test provides a minimally invasive window into tumor biology, but results must always be integrated with clinical presentation and radiological findings. I strongly recommend reviewing the complete report with your treating oncologist to ensure your treatment plan is both safe and personalized.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
Advisory & Medication Safety Notice
Do not discontinue or alter any prescribed medication, including immunotherapy or anticoagulants, without explicit consultation with your treating physician. This test is a diagnostic aid only and does not replace professional medical advice.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active severe infection, recent chemotherapy within 14 days (may transiently alter CTC counts), untreated severe anemia (Hb < 7 g/dL), known allergy to kit preservative.
- Emergency Red Flags: Acute onset of breathlessness, chest pain, or hemoptysis during or immediately after sample collection — immediately contact our hotline and seek emergency care.
Patient FAQ & Clinical Guidance
1. What is the OncoPro PD‑L1 CTC test?
This innovative liquid biopsy measures PD‑L1 expression on circulating tumor cells to predict immunotherapy response in advanced cancers. It detects and quantifies PD‑L1 protein on CTCs isolated from a simple blood draw, helping oncologists decide whether immune checkpoint inhibitors like pembrolizumab are likely to benefit the patient.
2. How should I prepare for the sample collection procedure?
You must complete the OncoPro Clinical Information Form (Form 32) and avoid refrigerating or freezing the sample. A trained phlebotomist will collect 8 mL of whole blood into a special EDTA tube containing preservative; keep the specimen at 18–22 °C and ship immediately. No fasting is required.
3. What do my results mean?
A positive PD‑L1 status indicates higher likelihood of benefiting from immune checkpoint inhibitors like pembrolizumab. The report provides the percentage of CTCs expressing PD‑L1 and a clinical interpretation; your oncologist will correlate this with other tests to plan therapy.
4. Is this test covered by insurance?
Coverage varies by insurer and plan. Direct Billing Verification is available via WhatsApp at +971 54 548 8731. Our insurance team will verify your eligibility and provide a cost estimate prior to scheduling.
5. How long does it take to get results?
Results are typically available within 21 working days from sample receipt at our ISO‑accredited laboratory. You will receive a telephonic post‑test clinical guidance session to help interpret the findings.
UAE Regulatory & Data Privacy Adherence
This test is fully compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. It is performed under the Medical Liability framework of Federal Decree‑Law No. 4 of 2016. Operated under DHA Facility License Number 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE.
Clinical & Logistical Metadata
| Test Name | OncoPro PD‑L1 Circulating Tumor Cells (CTC) Test |
| Price (AED) | 5,900 AED |
| Turnaround Time | 21 working days |
| Sample Type / Matrix | 8 mL whole blood in EDTA preservative tube |
| Methodology Used | Immunomagnetic Enrichment + PD‑L1 Immunofluorescence (LC‑MS/MS supported) |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of unspecified part of bronchus or lung) |
| LOINC Code | 96314-1 (PD‑L1 expression in Tumor cells) |
| DHA Facility License & Laboratory Address | 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians